会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Halogenated rhodamine derivatives and applications thereof
    • 卤化罗丹明衍生物及其应用
    • US08383672B2
    • 2013-02-26
    • US13157105
    • 2011-06-09
    • Abdelkrim HabiDenis GravelLuc VilleneuveHongsheng SuMarc Vaillancourt
    • Abdelkrim HabiDenis GravelLuc VilleneuveHongsheng SuMarc Vaillancourt
    • C07D311/88A61K31/35
    • A61K35/28A61K35/14C07D311/82
    • Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. Examples of rhodamine compounds include 2′-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4′,5′-dichloro-benzoic acid methyl ester hydrochloride; 4,5-dibromorhodamine 110 2-(2-methoxy ethoxy)ethyl ester hydrobromide; acetate salt of 2,7-dibromorhodamine B hexyl ester; acetate salt of 2,7-dibromorhodamine B methyl ester; 4,5-dibromorhodamine 6G hydrobromide; rhodamine B 3-bromopropyl; acetate salt 2,7-dibromo-4′-carboxytetramethylrosamine methyl ester; 4-bromo-5-phenyl rhodamine B methyl ester chloride; 2,7-dibromo-4,5-dimethyl rhodamine B methyl ester bromide; 2-bromo-7-ethynyl rhodamine B methyl ester bromide; and 4,5-dibromo-2,7-di-n-butyl rhodamine B methyl ester bromide.
    • 描述了用于治疗组织样品中的细菌感染的方法。 从患者收获的组织样品可能被细菌感染。 将罗丹明化合物与感染的组织样品混合以形成混合物。 然后将混合物暴露于辐射能以抑制或杀死细菌。 然后将暴露的混合物移植到患者体内。 罗丹明化合物的实例包括2' - (6-二甲基氨基-3-二甲基亚氨基-3H-呫吨-9-基)4',5'-二氯 - 苯甲酸甲酯盐酸盐; 4,5-二溴罗丹胺110 2-(2-甲氧基乙氧基)乙酯氢溴酸盐; 2,7-二溴罗丹明B己基酯的乙酸盐; 乙酸盐2,7-二溴罗丹明B甲酯; 4,5-二溴罗丹明6G氢溴酸盐; 罗丹明B 3 - 溴丙基; 乙酸盐2,7-二溴-4'-羧基四甲基甲胺甲酯; 4-溴-5-苯基罗丹明B甲酯氯化物; 2,7-二溴-4,5-二甲基罗丹明B甲酯溴化物; 2-溴-7-乙炔基罗丹明B甲酯溴化物; 和4,5-二溴-2,7-二正丁基罗丹明B甲酯溴化物。
    • 10. 发明授权
    • Modified GLP-1 peptides with increased biological potency
    • 具有增加的生物效能的修饰的GLP-1肽
    • US07067488B2
    • 2006-06-27
    • US10671340
    • 2003-09-25
    • Denis GravelKrishna PeriThierry AbribatAbdelkrim Habi
    • Denis GravelKrishna PeriThierry AbribatAbdelkrim Habi
    • A61K38/22C07K14/575
    • C07K14/605A61K38/26
    • The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof: X-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-val-Lys-Gly-Arg-Y (SEQ ID NO. 1) wherein X is a rigidifying hydrophobic moiety and wherein Y is selected from the group consisting of OH, NH2 and Gly-OH. Moreover, the present invention relates to pharmaceutical compositions comprising a therapeutically effective amount of a peptide of the present invention, or a pharmaceutically acceptable salt thereof, in association with at least one constituent selected from a pharmaceutically acceptable carrier, diluent, and excipient.
    • 本发明涉及具有下式的GLP-1肽或其药学上可接受的盐:<?in-line-formula description =“In-line formula”end =“lead”?> X-His-Ala- Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ala-Ala-Trp-Leu-val- Lys-Gly-Arg-Y(SEQ ID NO.1)<?in-line-formula description =“In-line Formulas”end =“tail”?>其中X是刚性疏水部分,其中Y选自 由OH,NH 2和Gly-OH组成的组。 此外,本发明涉及包含治疗有效量的本发明的肽或其药学上可接受的盐与至少一种选自药学上可接受的载体,稀释剂和赋形剂的成分的药物组合物。